327 Study of anti-PD-1 antibody multimodal combination as first-line treatment on time window of advanced solid tumor

327 Study of anti-PD-1 antibody multimodal combination as first-line treatment on time window of advanced solid tumor

Bibliographic Details
Main Authors:	Jian Shi, Junyan Wang, Baoen Shan, Jiayin Liu, Rongfeng Liu, Yujie Shan
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors
by: Rujiao Liu, et al.
Published: (2021-05-01)

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
by: Aung Naing, et al.
Published: (2019-08-01)

Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study
by: Min Yuan, et al.
Published: (2021-10-01)

Relatório de Estágio, 327 Creative Studio
by: Diana Raquel Salgado Cunha
Published: (2019)

Stub Record for Image YMCA_327.tif
Published: ()

Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
by: Bo Yang, et al.
Published: (2018-11-01)

Efficacy and Safety of Immune Checkpoint Inhibitors Therapy on Advanced Gastric Cancer or Gastroesophageal Junction Cancer: A Meta-analysis
by: SHAN Yujie, et al.
Published: (2021-02-01)

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.
by: Bert H O'Neil, et al.
Published: (2017-01-01)

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors
by: Jennifer Mataraza, et al.
Published: (2020-06-01)

Supraspinatus Tendinopathy in 327 Dogs: A Retrospective Study
by: Sherman O Canapp, et al.
Published: (2016-07-01)

Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies
by: Giuseppe Bellastella, et al.
Published: (2021-08-01)

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
by: Bhumsuk Keam, et al.
Published: (2020-06-01)

A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors
by: Xiao‐Li Wei, et al.
Published: (2020-08-01)

Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review
by: Francesco Spagnolo, et al.
Published: (2021-04-01)

Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody
by: Nalee Kim, et al.
Published: (2021-07-01)

Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies
by: Yumi Kambayashi, et al.
Published: (2019-07-01)

Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody
by: Kohei Fujita, et al.
Published: (2020-01-01)

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
by: He YY, et al.
Published: (2018-04-01)

High-quality NMR structure of human anti-apoptotic protein domain Mcl-1(171-327) for cancer drug design.
by: Gaohua Liu, et al.
Published: (2014-01-01)

Recent advances of bispecific antibodies in solid tumors
by: Shengnan Yu, et al.
Published: (2017-09-01)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
by: Janice M. Mehnert, et al.
Published: (2019-03-01)

SHR‐1316, an anti‐PD‐L1 antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study
by: Lan Mu, et al.
Published: (2021-05-01)

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
by: Bixia Tang, et al.
Published: (2019-01-01)

Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma
by: Jun Cai, et al.
Published: (2020-12-01)

Sintilimab: A Promising Anti-Tumor PD-1 Antibody
by: Lin Zhang, et al.
Published: (2020-11-01)

The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis
by: Run-Cong Nie, et al.
Published: (2020-01-01)

From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1—Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific?
by: Lishi Wang, et al.
Published: (2021-09-01)

The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies
by: Xuan Wang, et al.
Published: (2020-09-01)

Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
by: Arun Rajan, et al.
Published: (2019-10-01)

Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab
by: Stefan Schreiber, et al.
Published: (2020-06-01)

0.4°S 32.7°E: Cenzorin in njegova »astronomska« opažanja
by: Gregor Pobežin
Published: (2014-07-01)

Research Advances of IL-8 and Its Receptors in Tumor Progression and Treatment
by: YANG Qing, et al.
Published: (2019-01-01)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
by: Hyun Tae Lee, et al.
Published: (2017-07-01)

Review of the Combination Strategies Used in Anti-PD1/PD-L1 Monoclonal Antibody Treatment
by: Cheng Jiaxing
Published: (2020-01-01)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
by: Justin C. Moser, et al.
Published: (2019-12-01)

The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer
by: Chongya Zhai, et al.
Published: (2021-02-01)

Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
by: Yuyin Fu, et al.
Published: (2021-07-01)

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
by: Kazushige Yoshida, et al.
Published: (2020-01-01)

Diffuse granulomatous panniculitis associated with anti PD-1 antibody therapy
by: Baijia Jiang, MD, et al.
Published: (2018-01-01)

Switching administration of anti‐PD‐1 and anti‐PD‐L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: Case series and literature review
by: Shingo Kitagawa, et al.
Published: (2020-07-01)